STOCK TITAN

Immunic, Inc. to Participate in Investor and Scientific Conferences in September

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in September:

  • September 13-15: H.C. Wainwright 23rd Annual Global Investment Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview at the conference. The on-demand presentation will be available for viewing beginning September 13, at 7:00 am ET. An audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
     
  • September 22-25: 50th Annual European Society for Dermatological Research (ESDR) Meeting. Irina Betscheider, Ph.D., Clinical Operations Program Lead at Immunic, will present the first clinical experience with IMU-935, an orally available, selective inverse agonist of RORγt. The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations.
    • Poster Number: ESDR057
    • Title: Safety, tolerability and pharmacokinetics of single and multiple oral doses of IMU-935 in healthy volunteers: First clinical experience with an orally available small molecule inhibitor of IL-17
       
  • September 27-30: 2021 Cantor Virtual Global Healthcare Conference. Dr. Vitt will participate in a fireside chat on Tuesday, September 28, at 10:00 am ET. A live audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's participation in investor and scientific conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com

US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com

Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-investor-and-scientific-conferences-in-september-301370253.html

SOURCE Immunic, Inc.

Immunic Inc

NASDAQ:IMUX

IMUX Rankings

IMUX Latest News

IMUX Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Pharmaceuticals: Major, Health Technology, Manufacturing, Pharmaceutical Preparation Manufacturing
Germany
Martinsried

About IMUX

immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu